Skip to content Skip to sidebar Skip to footer

Healthcare Stocks

Fisher and Paykel (ASX:FPH): It exports sleep apnea products to 120 countries, but here’s why ResMed is a better buy

If there was one ASX company brutally honest about the fact that it could not escape an impact from Trump's tariffs, it was Fisher and Paykel (ASX:FPH). Of course, this was not just because of the tariffs themselves but forex movements and the economic environment. FPH shares fell over 15% in just two months from mid-January…

ByNick SundichJanuary 22, 2026

Anteris Technologies (ASX: AVR) Surges 30% on Medtronic Deal- Is It a Buy?

Anteris Technologies Gains Momentum with Medtronic Partnership Anteris Technologies (ASX: AVR) jumped more than 30% after announcing a deal that could change its future. The Australian heart valve company secured a massive US$290 million funding package. This included US$200 million from the public and a US$90 million direct investment from Medtronic, the world's largest medical…

ByUjjwal MaheshwariJanuary 22, 2026

Epiminder (ASX:EPI): Less than 2 months since its IPO, this medtech made its first implant

Epiminder (ASX:EPI) only listed on the ASX at the end of November last year, but just announced to market that it completed the first implant of its Minder system in the USA. The company's Minder system is an epilepsy monitoring technology which is in a global clinical trial which will enrol over 200 patients. Shares only…

ByNick SundichJanuary 21, 2026

Osteopore (ASX:OSX) Secures A$2.6M China Deal: Micro-Cap Opportunity or Too Risky to Buy?

Osteopore signs a major China distribution deal, but risks remain Osteopore (ASX: OSX) surged 71 per cent last Friday after announcing an exclusive distribution deal with Majeton Limited valued at above RMB 12 million (approximately A$2.6 million). The agreement covers China, Hong Kong, and Macau. For a company with a market capitalisation of just A$2.4…

ByUjjwal MaheshwariJanuary 19, 2026

Proteomics International (ASX:PIQ) Appoints New CEO as US Sales Push Begins: Is It Time to Buy?

Proteomics International begins its US sales push as Medicare reimbursement starts At Proteomics International (ASX: PIQ), new CEO David Morris takes the reins today as the Perth-based medical technology company shifts from research and development to commercial execution. This leadership change comes at a critical time, as US Medicare reimbursement of US$390.75 per test went live…

ByUjjwal MaheshwariJanuary 19, 2026

Zelira Therapeutics (ASX:ZLD) A 170% Surge Backed by Smart, Non-Dilutive Funding

External Validation Sends Shares Flying Zelira Therapeutics shares surged as much as 172% intraday, before settling around 73.5 cents, following a major funding announcement that the market clearly interpreted as far more than just another capital raise. The company announced that its HOPE 1 special purpose vehicle had secured approximately US$33 million in committed capital from…

ByCharlie YouldenJanuary 16, 2026

5 ASX Healthcare Companies with Game Changing Milestones in 2026!

2026 is set to be a big year for several ASX Healthcare Companies, especially companies in the pre-commercialisation stage. The two keys to get drugs or devices to market are to pass clinical trials and obtain regulatory approval. This article takes a look at 5 of the most exciting of those companies. What are the Best…

ByNick SundichJanuary 15, 2026

Singular Health (ASX:SHG) Gains FDA Clearance for Cloud Imaging Platform: Is This MedTech a Buy Now?

Singular Health secures FDA clearance for US rollout Singular Health Group (ASX: SHG) grabbed investor attention on Tuesday after the company announced FDA 510(k) clearance for its 3DICOM MD Cloud platform. Shares surged as high as A$0.30 in early trade, representing a 15% intraday gain, before profit-taking pulled the stock back to close at A$0.26.…

ByUjjwal MaheshwariJanuary 14, 2026

Telix Pharmaceuticals (ASX:TLX) Through the Commercialisation Chasm

The Market Lost Patience, the Strategy Did Not Telix Pharmaceuticals (ASX:TLX) is one of the more compelling examples of a biotech company pushing through the commercialisation chasm, often the most difficult phase in the sector’s lifecycle. This is the point where companies transition from deep, equity-funded cash burn into sustainable revenue generation, and many fail…

ByCharlie YouldenJanuary 13, 2026

EBR Systems (ASX:EBR) Surges 7.6% on Q4 Momentum: Time to Buy Before Full US Launch?

EBR Systems Gains Momentum Ahead of 2026 US Launch EBR Systems (ASX: EBR) is building serious momentum as it moves closer to a full US commercial launch in 2026. Shares jumped 7.6 per cent on Monday to AUD 1.06, up from a previous close of AUD 0.98, as investors responded to strong Q4 adoption numbers.…

ByUjjwal MaheshwariJanuary 13, 2026

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Fisher and Paykel (ASX:FPH): It exports sleep apnea products to 120 countries, but here’s why ResMed is a better buy

Anteris Technologies (ASX: AVR) Surges 30% on Medtronic Deal- Is It a Buy?

Epiminder (ASX:EPI): Less than 2 months since its IPO, this medtech made its first implant

Osteopore (ASX:OSX) Secures A$2.6M China Deal: Micro-Cap Opportunity or Too Risky to Buy?

Proteomics International (ASX:PIQ) Appoints New CEO as US Sales Push Begins: Is It Time to Buy?

Zelira Therapeutics (ASX:ZLD) A 170% Surge Backed by Smart, Non-Dilutive Funding

5 ASX Healthcare Companies with Game Changing Milestones in 2026!

Singular Health (ASX:SHG) Gains FDA Clearance for Cloud Imaging Platform: Is This MedTech a Buy Now?

Telix Pharmaceuticals (ASX:TLX) Through the Commercialisation Chasm

EBR Systems (ASX:EBR) Surges 7.6% on Q4 Momentum: Time to Buy Before Full US Launch?

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Add Your Heading Text Here